Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hiroyuki Koshio

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics

Cancer Research

Oncology

2019

English

Related publications

Dual Inhibition of EGFR With Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations

Cancer Discovery

Oncology

2014

English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology

English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research

Cancer Research

Oncology

2015

English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations

Scientific Reports

Multidisciplinary

2019

English

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined With EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer

Biomedical Journal of Scientific & Technical Research

2019

English

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hiroyuki Koshio

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Related publications

Dual Inhibition of EGFR With Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined With EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC